All Episodes

osTEAo: Spooky Sarcoma Stories

A Phase 1 Trial evaluating Folate Receptor Alpha CAR T cells for Advanced Osteosarcoma

MISTOSUS: A phase II clinical trial of IscadorP (Mistletoe extract) as immunotherapy to improve event-free survival in patients with relapsed resectable osteosarcoma

osTEAo: Let's Talk Childhood Cancer

A Phase 1b Study of Tegavivint, a TBL1 Inhibitor, with Gemcitabine in Patients with Relapsed or Refractory Osteosarcoma (TIGER)

CCDI Data Ecosystem in Action: Enabling Data-Driven Discovery

Functional Precision Medicine for Osteosarcoma

osTEAo: Same Summer, Different View

Dissecting and Targeting Metastatic Drivers in Osteosarcoma

Validation of MCL1 inhibition and combinatorial therapy for elimination of osteosarcoma lung metastasis

Combinatorial immunotherapy to overcome cellular therapy resistance in osteosarcoma

Epigenetic Regulation of the Type I Interferon Pathway in Osteosarcoma: Implications for Immune Checkpoint Blockade

osTEAo: Live from FACTOR '26!

osTEAo: Advocacy Doesn't End at Discharge

Your Story, Your Tissue, Your Impact: Changing the Future of Osteosarcoma

A Guide to FACTOR 2026 Scientific Panels

osTEAo - More Than Physical: The Mental Toll of Cancer

A Phase 1/2, Study to Evaluate LNTH-2403, a LRRC15-targeted radiopharmaceutical, in Patients with Relapsed/Refractory Osteosarcoma

Defining tumor-specific vulnerabilities by mapping oncogenic structural variation in osteosarcoma

Targeting Perioperative Myeloid Responses Through NOD/RIPK2 Modulation to Prevent Metastatic Progression in Osteosarcoma

osTEAo: The Sound of Strength

Zanzalintinib in Osteosarcoma: Balancing Disease Control and Quality of Life

Extracellular Matrix Degradation to Overcome Osteosarcoma Chemoresistance

Targeting EPHA2 with dual-armored CAR T cells for immunotherapy in pediatric osteosarcoma

Identifying mechanisms of chemoresistance in metastatic osteosarcoma using molecular barcoding

New insights into shared molecular and genomic features between humans and dogs with OS

Implementing personalized, adaptive therapies in osteosarcoma

osTEAo: The Sibling Side of Cancer

High-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches

osTEAo: New Year, Same Cancer

Next generation dual-CAR gamma delta T cells for the treatment of pediatric osteosarcoma

Insights from the Musculoskeletal Tumor Society (MSTS) December 2025 Annual Meeting

Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma

Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution

osTEAo: Navigating Loss in the AYA Community

Synergy of ATM and PARP Inhibitors in Pediatric Osteosarcoma

Comparative extracellular vesicle (EV) biomarkers for osteosarcoma risk and prognosis

osTEAo - Spooky Sarcoma Stories

Insights from the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer

Phase 1/2 clinical trial to evaluate the safety and efficacy of domatinostat in combination with sirolimus in adolescents and adults with relapsed, refractory sarcoma

osTEAo - Turning Pain Into Purpose

Distinct patterns of chromosomal instability fuel osteosarcoma progression and influence patient outcomes

Deciphering the impact of STING agonists on the tumor microenvironment in osteosarcoma

osTEAo: The Fault in Our Scars - Dating & Cancer

Clinical biomarkers for osteosarcoma stratification (cBOSS): Insights from a working group

Simultaneous targeting of CDK4/6 and BETs is independent of RB status in osteosarcoma

osTEAo: When Positivity Silences Pain

Old drugs, new tricks? A novel immunomodulatory approach to relapsed osteosarcoma therapy

Molecular subtyping of osteosarcoma, ecDNA and more

osTEAo: What to Expect When You're Not Expecting

A Guide to the FACTOR 2025 Scientific Panels with Matteo Trucco, MD

Autologous Cancer Vaccine with Checkpoint Inhibitor for Treatment of Canine Osteosarcoma

Stuck on the Sidelines: AYA Cancer & FOMO

Surgical Options and Advances in Osteosarcoma (La Cirugía de Salvamento de Extremidades)

Advocating for Cures: How You Can Support the Give Kids a Chance Act and Advance Pediatric Cancer Research

Tumor cGAS-STING repression drives immune evasion in osteosarcoma and is therapeutically targetable via host STING activation

osTEAo: Accessibility Wins, Fails & WTF Moments

Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: Consensus Recommendations from the Children’s Oncology Group Bone Tumour Committee

Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis

Multi-modal omics analysis identifies targetable sensory neuron circuitry that promotes sarcoma disease progression

osTEAo: Paws and Reflect: How Pets Help Us Heal

An Organoid-based Functional Precision Medicine Trial in Osteosarcoma (PREMOST)

Minimally Invasive Metastasectomy in Canines (MIMIC)

Live-cell whole tissue models reveal sources of dynamic signaling heterogeneity and single cell drug response variation in the metastatic niche

osTEAo: Cancer Fatigue: How to Escape the Cancerverse

COG Blueprint for Research on Bone Tumors

Understanding Tumor Evolution in Osteosarcoma

Macrophage engineered vesicles to treat pediatric Osteosarcoma.

osTEAo: Hospital Holidays

Repurposing Virus Specific T cells as Immune Therapy for Osteosarcoma

Repurposing Drugs for Osteosarcoma

The ablative and immunomodulatory effects of histotripsy treatment in osteosarcoma

osTEAo: Spooky Sarcoma Stories

Molecular and cellular deconstruction of metastatic osteosarcoma

osTEAo: Back to School: Cancer + Curriculum

Fit for Filing Academic Clinical Trials: An Industry Perspective

Magnetic Resonance Guided (MRg) High Intensity Focused Ultrasound (HIFU) For Palliation of Canine Appendicular Osteosarcoma

osTEAo - Clear Scans…So Now What?

Clinical Utility of Functional Precision Medicine to Guide Treatments for Osteosarcoma Patients

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy

A Multi-Institution Study in Combination with Relapsed or Refractory Pediatric Bone and Soft Tissue

osTEAo: The Sibling Situation

Genomes, Avatars and AI: The Future of Personalized Medicine

Exploring Novel Immunotherapies for Canine Osteosarcoma

A Guide to the FACTOR 2024 Scientific Panels with Matteo Trucco, MD

osTEAo: Long Term Side Effects from Treatment For Osteosarcoma and AYA Cancer

Creating a translational genomic framework for canine osteosarcoma: updates on the NCI DOG2 project

Positioning Poly-(ADP)-ribose polymerase inhibitors (PARPi) for the treatment of Osteosarcoma

TGF-beta inhibition as a novel therapeutic option in Osteosarcoma

Out on a Limb - Travel Tips for AYA Cancer Patients

Phase 1 Study of Cabozantinib in Combination with Topotecan-Cyclophosphamide for Patients with Relapsed or Refractory Ewing Sarcoma or Osteosarcoma

Targeting Urea Cycle Dysfunction to Prevent and Treat Osteosarcoma Metastasis

osTEAo: Patient Experiences with Lung Surgery for Osteosarcoma

Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research

Patient perspectives on participating in research and clinical trials

Tissue Engineering Strategies for Elucidating Osteosarcoma Biology and Drug Discovery

Liquid biopsy in Ewing sarcoma and osteosarcoma as a prognostic and response diagnostic: The LEOPARD Study

Managing Stress in AYA Cancer Patients

Prevention of Cisplatin-induced Hearing Loss: Implications for Young People Treated for Osteosarcoma

TACOS: A Phase 2 Trial of Atezolizumab and Cabozantinib in OsteoSarcoma